Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Intervention(s) in this Clinical Trial

• Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Inclusion Criteria:

• Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

• Patients not meeting above stated age criteria
• Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
• History of serious ocular, neurological, cardiovascular disease
• History of severe systemic disease
• History of arrhythmias or high blood pressure
• Patients currently taking any type of ocular or systemic medications except multivitamins.
• Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 50 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Investigator: Walter Reed Army Medical Center U.S. Fed

Overall Clinical Trial Officials and Contacts

KRAIG S. BOWER, MD Principal Investigator Walter Reed Army Medical Center  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00413751

Study ID Number: WRAMC WU #03-23004

ClinicalTrials.gov Identifier: NCT00413751

Health Authority: United States: Federal Government